Calidi Biotherapeutics Appoints New CEO Eric Poma

Calidi Biotherapeutics ( (CLDI) ) just unveiled an announcement.

On April 17, 2025, Allan Camaisa announced his resignation as CEO and Chairman of Calidi Biotherapeutics, effective April 21, 2025, while remaining a board member. Eric Poma, Ph.D., was appointed as the new CEO and Class I director, effective April 22, 2025. Poma brings over 30 years of experience in the biopharmaceutical industry, previously serving as CEO of Molecular Templates. His appointment is expected to drive Calidi’s clinical and preclinical programs forward, leveraging his expertise in oncology and capital fundraising. The transition is part of Calidi’s strategy to advance its virotherapy platform and clinical trials, aiming to enhance shareholder value and strengthen its market position.

Spark’s Take on CLDI Stock

According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.

Calidi Biotherapeutics faces substantial financial and technical challenges, with significant risks due to lack of revenue and profitability. However, recent corporate developments and strategic advancements in clinical programs offer some optimism for the future.

To see Spark’s full report on CLDI stock, click here.

More about Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California. It specializes in developing proprietary stem cell-based platforms that utilize oncolytic viruses to treat various oncology indications, including high-grade gliomas and solid tumors. The company’s technology aims to enhance the efficacy and safety of cancer treatments by leveraging allogeneic stem cells to deliver therapeutic payloads.

YTD Price Performance: -60.25%

Average Trading Volume: 1,207,579

Technical Sentiment Signal: Buy

Current Market Cap: $15.75M

For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.